Pyoderma

Summary

Pyoderma (MONDO:0002922) is a disease (an umbrella term covering 5 Mondo subtypes) and 7 clinical trials. Top therapeutic interventions include baricitinib, guselkumab, and dioxydine. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pyoderma
Mondo ID	MONDO:0002922
MeSH	D011711
DOID	DOID:4223
ICD-10-CM	L08.0
ICD-11	1991248382
SNOMED CT	70759006
UMLS	C0034212
MedGen	18783
Is cancer (heuristic)	no

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › pyoderma

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (5): cutaneous diphtheria, carbuncle, erythrasma, impetigo, pyoderma gangrenosum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Adalimumab	Phase 3 (in late-stage trials)
Dioxydine	Phase 3 (in late-stage trials)
Gevokizumab	Phase 3 (in late-stage trials)
Oxygen	Phase 3 (in late-stage trials)
Vilobelimab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bermekimab, Canakinumab, Etrasimod, Ixekizumab, Secukinumab, Spesolimab.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2
PHASE4	1
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00202891	PHASE4	WITHDRAWN	Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)
NCT05561816	PHASE3	COMPLETED	Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
NCT06563323	PHASE2	RECRUITING	Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
NCT04901325	PHASE2	COMPLETED	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
NCT04895566	EARLY_PHASE1	COMPLETED	Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
NCT02280733	Not specified	RECRUITING	A Real-World Registry of Chronic Wounds and Ulcers
NCT00884728	Not specified	COMPLETED	Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia’s Northern Territory

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BARICITINIB	4	1
GUSELKUMAB	4	1
DIOXYDINE	3	1
SISOMICIN	3	1
CHEMBL5427854	0	1